Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus
Yutaka Mizuki, Shinji Sakamoto, Yuko Okahisa, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 5, pp. 367-382
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management
Vaios Peritogiannis, Angeliki Ninou, Maria Samakouri
Healthcare (2022) Vol. 10, Iss. 12, pp. 2366-2366
Open Access | Times Cited: 44
Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review
Octavian Vasiliu
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 1
Open Access | Times Cited: 38
Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders
Qian Chen, Ting Cao, Nana Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 38
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction
Kah Kheng Goh, Cynthia Yi-An Chen, Tzu‐Hua Wu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7092-7092
Open Access | Times Cited: 24
Metabolic biomarkers of clinical outcomes in severe mental illness (METPSY): protocol for a prospective observational study in the Hub for metabolic psychiatry
Arish Mudra Rakshasa-Loots, Carel Roché Steyn, Duncan Swiffen, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
Associations between participation in a diabetes pay-for-performance program and health outcomes and healthcare utilization among people with comorbid schizophrenia and type 2 diabetes in Taiwan
Hui‐Min Hsieh, Yu-Hsin Wang, Hsueh‐Fen Chen
General Hospital Psychiatry (2025)
Closed Access
Association between serum bilirubin and type 2 diabetes mellitus risk: Findings from a schizophrenia cohort
Kuan Liu, Hao Chen, Shi-Ao Wang, et al.
Schizophrenia Research (2025) Vol. 279, pp. 106-115
Closed Access
Schizophrenia as a risk factor for cardiovascular and metabolic health outcomes: a comparative risk assessment
Suhailah Ali, Damian Santomauro, Alize J Ferrari, et al.
Epidemiology and Psychiatric Sciences (2023) Vol. 32
Open Access | Times Cited: 12
βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia
Jessica Di Re, Michela Marini, Syed Ibrar Hussain, et al.
Molecular Psychiatry (2025)
Open Access
Orphan G Protein-Coupled Receptor GPR88: Mapping Its Significance in Central Nervous System Disorders
Yanli Zhao, Dongxu Yue, Yingying Zou
Molecular Neurobiology (2025)
Closed Access
Exosome and exosomal contents in schizophrenia
Tingkai Zhang, Yehong Fang, Liangliang Wang, et al.
Journal of Psychiatric Research (2023) Vol. 163, pp. 365-371
Closed Access | Times Cited: 9
Integrating Electronic Health Records and Polygenic Risk to Identify Genetically Unrelated Comorbidities of Schizophrenia That May Be Modifiable
Tess Vessels, Nick Strayer, Hyunjoon Lee, et al.
Biological Psychiatry Global Open Science (2024) Vol. 4, Iss. 3, pp. 100297-100297
Open Access | Times Cited: 3
Predicting type 2 diabetes prevalence for people with severe mental illness in a multi-ethnic East London population
Diana Shamsutdinova, Jayati Das‐Munshi, Mark Ashworth, et al.
International Journal of Medical Informatics (2023) Vol. 172, pp. 105019-105019
Open Access | Times Cited: 7
Psychische und neurokognitive Erkrankungen und Diabetes mellitus (Update 2023)
Heidemarie Abrahamian, Alexandra Kautzky‐Willer, Angelika Rießland-Seifert, et al.
Wiener klinische Wochenschrift (2023) Vol. 135, Iss. S1, pp. 225-236
Open Access | Times Cited: 7
Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Yanli Niu, Ye Zhang, Zhiyong Song, et al.
Iranian Journal of Public Health (2024)
Open Access | Times Cited: 2
Genomic insights into the comorbidity between type 2 diabetes and schizophrenia
Ana Luiza Arruda, Golam M. Khandaker, Andrew P. Morris, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Schizophrenia and type 2 diabetes risk: a systematic review and meta-analysis
Kai Dong, Shenghai Wang, Chunhui Qu, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 2
Associations between major psychiatric disorder polygenic risk scores and blood-based markers in UK biobank
Michael D.E. Sewell, Lorena Jiménez‐Sánchez, Xueyi Shen, et al.
Brain Behavior and Immunity (2021) Vol. 97, pp. 32-41
Open Access | Times Cited: 16
Cognitive deficits among people with schizophrenia and prediabetes or diabetes
Alexander John, Thynn Mya, Darren Haywood
Acta Psychiatrica Scandinavica (2023) Vol. 149, Iss. 1, pp. 65-76
Open Access | Times Cited: 5
Evidence that the pituitary gland connects type 2 diabetes mellitus and schizophrenia based on large-scale trans-ethnic genetic analyses
Lei Cai, Yanlan Sun, Yonglin Liu, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 8
Genomic and Reverse Translational Analysis Discloses a Role for Small GTPase RhoA Signaling in the Pathogenesis of Schizophrenia: Rho-Kinase as a Novel Drug Target
Rinako Tanaka, Kiyofumi Yamada
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15623-15623
Open Access | Times Cited: 4
Physical health monitoring for people with schizophrenia
David Castle, A.-N. Li
Australian Prescriber (2023) Vol. 46, Iss. 4, pp. 75-79
Open Access | Times Cited: 4
The volume of gray matter mediates the relationship between glucolipid metabolism and neurocognition in first-episode, drug-naïve patients with schizophrenia
Hailing Cao, Yajing Meng, Yamin Zhang, et al.
Journal of Psychiatric Research (2024) Vol. 172, pp. 402-410
Closed Access | Times Cited: 1
Integrative analysis to identify shared mechanisms between schizophrenia and bipolar disorder and their comorbidities
Vinay Srinivas Bharadhwaj, Sarah Mubeen, Astghik Sargsyan, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 122, pp. 110688-110688
Open Access | Times Cited: 7
Effect of H2H management mode on blood sugar control and living ability in patients with schizophrenia and type 2 diabetes mellitus.
Lifeng Yang, Juan Wang, Han Li, et al.
PubMed (2023) Vol. 15, Iss. 1, pp. 223-232
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top